Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1981 1
1982 1
1983 1
1984 2
1986 3
1987 5
1988 5
1989 3
1990 7
1991 6
1992 6
1993 5
1994 6
1995 3
1996 4
1997 10
1998 5
1999 3
2000 4
2001 2
2002 7
2003 5
2004 4
2005 2
2006 1
2007 4
2008 3
2009 2
2010 1
2011 7
2012 5
2013 6
2014 2
2015 4
2016 5
2017 7
2018 4
2019 5
2020 1
2021 4
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant hyperthermia, susceptibility to, 5"
Page 1
Malignant hyperthermia: a review.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Rosenberg H, et al. Orphanet J Rare Dis. 2015 Aug 4;10:93. doi: 10.1186/s13023-015-0310-1. Orphanet J Rare Dis. 2015. PMID: 26238698 Free PMC article. Review.
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine, a …
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to pot …
Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists.
Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, McGrady E. Hopkins PM, et al. Anaesthesia. 2021 May;76(5):655-664. doi: 10.1111/anae.15317. Epub 2021 Jan 5. Anaesthesia. 2021. PMID: 33399225 Free article.
Malignant hyperthermia is defined in the International Classification of Diseases as a progressive life-threatening hyperthermic reaction occurring during general anaesthesia. Malignant hyperthermia has an underlying genetic basis, and genetically s …
Malignant hyperthermia is defined in the International Classification of Diseases as a progressive life-threatening hypertherm …
Malignant Hyperthermia Update.
Ellinas H, Albrecht MA. Ellinas H, et al. Anesthesiol Clin. 2020 Mar;38(1):165-181. doi: 10.1016/j.anclin.2019.10.010. Anesthesiol Clin. 2020. PMID: 32008650 Review.
Malignant hyperthermia (MH) is a rare but potentially lethal skeletal muscle disorder affecting calcium release channels. ...Current data suggest that mortality has improved to less than 5%. The gold standard for ruling out MH is the contracture test. ...
Malignant hyperthermia (MH) is a rare but potentially lethal skeletal muscle disorder affecting calcium release channels. ...C …
Malignant hyperthermia.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Rosenberg H, et al. Orphanet J Rare Dis. 2007 Apr 24;2:21. doi: 10.1186/1750-1172-2-21. Orphanet J Rare Dis. 2007. PMID: 17456235 Free PMC article. Review.
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely, i …
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to pot …
Malignant hyperthermia.
Ali SZ, Taguchi A, Rosenberg H. Ali SZ, et al. Best Pract Res Clin Anaesthesiol. 2003 Dec;17(4):519-33. doi: 10.1016/j.bpa.2003.09.012. Best Pract Res Clin Anaesthesiol. 2003. PMID: 14661655 Review.
Malignant hyperthermia (MH) is an uncommon, life-threatening, acute pharmacogenetic disorder of the skeletal muscle cell. ...The ryanodine receptor, the calcium-release channel of the sarcoplasmic reticulum, is the primary locus for malignant hypothermia s …
Malignant hyperthermia (MH) is an uncommon, life-threatening, acute pharmacogenetic disorder of the skeletal muscle cell. ...T …
Malignant hyperthermia.
Halliday NJ. Halliday NJ. J Craniofac Surg. 2003 Sep;14(5):800-2. doi: 10.1097/00001665-200309000-00039. J Craniofac Surg. 2003. PMID: 14501352
Malignant Hyperthermia (MH) has been a recognized complication of general anesthesia after the first case reports in the 1940's. ...The caffeine/halothane testing of muscle biopsies is currently the most definitive test for malignant hyperthermia su …
Malignant Hyperthermia (MH) has been a recognized complication of general anesthesia after the first case reports in the 1940' …
Malignant hyperthermia.
Gronert GA. Gronert GA. Anesthesiology. 1980 Nov;53(5):395-423. doi: 10.1097/00000542-198011000-00007. Anesthesiology. 1980. PMID: 6999950 Free article. Review.
Sympathetic involvement in MH, while controversial, is probably a response to stress that affects blood flow, heat loss, and myocardial function, rather than a direct sympathetic activation of susceptible muscle. Diagnosis is based upon extraordinary temperature and acid-b …
Sympathetic involvement in MH, while controversial, is probably a response to stress that affects blood flow, heat loss, and myocardial func …
Malignant hyperthermia when dantrolene is not readily available.
Gong X. Gong X. BMC Anesthesiol. 2021 Apr 16;21(1):119. doi: 10.1186/s12871-021-01328-3. BMC Anesthesiol. 2021. PMID: 33863282 Free PMC article.
BACKGROUND: Malignant hyperthermia is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hypermetabolic reactions and commonly triggered in susceptible individuals by volatile anesthetics or succinylcholine, or both. ...METH …
BACKGROUND: Malignant hyperthermia is a rare but life-threatening pharmacogenetic muscle disorder characterized by abnormal hy …
Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.
Beam TA, Loudermilk EF, Kisor DF. Beam TA, et al. Physiol Genomics. 2017 Feb 1;49(2):81-87. doi: 10.1152/physiolgenomics.00126.2016. Epub 2016 Dec 23. Physiol Genomics. 2017. PMID: 28011884 Review.
A review of the pharmacogenetics (PGt) and pathophysiology of calcium voltage-gated channel subunit alpha1 S (CACNA1S) mutations in malignant hyperthermia susceptibility type 5 (MHS5; MIM #60188) is presented. Malignant hyperthermia (MH) …
A review of the pharmacogenetics (PGt) and pathophysiology of calcium voltage-gated channel subunit alpha1 S (CACNA1S) mutations in malig …
Congenital myopathies: not only a paediatric topic.
Jungbluth H, Voermans NC. Jungbluth H, et al. Curr Opin Neurol. 2016 Oct;29(5):642-50. doi: 10.1097/WCO.0000000000000372. Curr Opin Neurol. 2016. PMID: 27538056 Review.
PURPOSE OF REVIEW: This article reviews adult presentations of the major congenital myopathies - central core disease, multiminicore disease, centronuclear myopathy and nemaline myopathy - with an emphasis on common genetic backgrounds, typical clinicopathological f …
PURPOSE OF REVIEW: This article reviews adult presentations of the major congenital myopathies - central core disease, multiminicore …
164 results